Want a deeper scan?
Get a guided tour of your organization’s security posture from an UpGuard team member.

Clovis Oncology

This is a preliminary report on Clovis Oncology’s security posture. If you want in-depth, always up-to-date reports on Clovis Oncology and millions of other companies, start a free trial today. UpGuard is the new standard in third-party risk management and attack surface management. Our security ratings engine monitors billions of data points each day.
Start monitoring Clovis Oncology

UpGuard Security Rating

/ 950
This is a 0-950 security rating for Clovis Oncology. The higher the rating, the more likely Clovis Oncology has good security practices. For complete visibility of the security posture of Clovis Oncology, start a free trial of UpGuard.

Company info

Clovis Oncology
Clovis Oncology
Last updated
Last updated
Last updated today

Security report for Clovis Oncology

Rociletinib is a medication developed to treat non-small cell lung carcinomas with a specific mutation. It is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor.
Last updated today

Clovis Oncology Data Breaches and Security News

Relevant news, breaches and security articles relating to Clovis Oncology.

More security reports

Compare Clovis Oncology's security performance with other companies.

Leader in Third Party & Supplier Risk Management Software

See how UpGuard shapes up against other platforms in the market.
Free instant security score

How secure is your organization?

Request a free cybersecurity report to discover key risks on your website, email, network, and brand.
  • Check icon
    Instant insights you can act on immediately
  • Check icon
    Hundreds of risk factors including email security, SSL, DNS health, open ports and common vulnerabilities
Website Security scan resultsWebsite Security scan rating
Want a full vendor security report for this company?
Start your free trial and unlock real-time insights to identify and assess vendor risks.